Eric W. Price

Eric W. Price

Auto-generated profile, based on publicly available information

Eric W. Price

Department of Chemistry, University of Saskatchewan, Saskatoon, Saskatchewan S7N-5C9, Canada

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2020 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
SSSai Kiran Sharma
Sai Kiran Sharma
JGJonathan M. Glaser
Jonathan M. Glaser
KEKimberly J. Edwards
Kimberly J. Edwards
ESElaheh Khozeimeh Sarbisheh
Elaheh Khozeimeh Sarbisheh
ASAkam K. Salih
Akam K. Salih
EPEric W. Price
Eric W. Price

9 March 2017 in Journal of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
EPEric W. Price
Eric W. Price
KCKathryn E. Carnazza
Kathryn E. Carnazza
SCSean D. Carlin
Sean D. Carlin
ACAndrew Cho
Andrew Cho
KEKimberly J. Edwards
Kimberly J. Edwards
JLJason S. Lewis
Jason S. Lewis
Objectives: The hepatocyte growth factor (HGF) binding antibody rilotumumab (AMG102) was modified for use as an 89Zr-based immuno-PET (positron emission tomography) imaging agent to non-invasively determine the local levels of HGF protein in tumors. As recent clinical trials of HGF targeting therapies have been largely unsuccessful in several different cancers (e.g., gastric, brain, lung), we have synthesized and validated 89Zr-DFO-AMG102 as a companion diagnostic for improved identification and selection of patients having high local levels of HGF in tumors. To date, patient selection has not been performed using the local levels of HGF protein in tumors. Methods: The chelator p-SCN-Bn-DFO was conjugated to AMG102, radiolabeling with 89Zr was performed in high radiochemical yields and purity (>99%), and binding affinity of the modified antibody was confirmed using an enzyme-linked immunosorbent assay (ELISA) type binding assay. PET imaging, biodistribution, autoradiography and immunohistochemistry, and ex vivo HGF-ELISA experiments were performed in murine xenografts of U87MG (HGF positive (+), MET positive (+)), MKN45 (HGF negative (-), MET +), and 4 patient-derived xenografts (PDX, MET+, HGF unknown). Results: Tumor uptake of 89Zr-DFO-AMG102 at 120 h p.i. in U87MG xenografts (HGF+) was high (36.8 ± 7.8 % injected dose per gram (ID/g)), while uptake in MKN45 xenografts (HGF-) was 5.0 ± 1.3 %ID/g, and a control of non-specific human IgG 89Zr-DFO-IgG in U87MG tumors was 11.5 ± 3.3 %ID/g, demonstrating selective uptake in HGF+ tumors. Similar experiments performed in 4 different gastric cancer PDX models showed low uptake of 89Zr-DFO-AMG102 (~4-7 %ID/g), which corresponded with low HGF levels in these tumors (ex vivo ELISA). Autoradiography, immunohistochemical staining, and HGF-ELISA assays confirmed that elevated levels of HGF protein were only present in U87MG tumors, and that 89Zr-DFO-AMG102 uptake was closely correlated with HGF protein levels in tumors. Conclusions: The new immuno-PET imaging agent 89Zr-DFO-AMG102 was successfully synthesized, radiolabeled, and validated in vitro and in vivo to selectively accumulate in tumors with high local levels of HGF protein. These results suggest that 89Zr-DFO-AMG102 would be a valuable companion diagnostic tool for the non-invasive selection of patients with elevated local concentrations of HGF in tumors for planning any HGF-targeted therapy, with the potential to improve clinical outcomes.

28 July 2020 in Inorganic Chemistry
Verified
Journal Article
Closed access
ESElaheh Khozeimeh Sarbisheh
Elaheh Khozeimeh Sarbisheh
ASAkam K. Salih
Akam K. Salih
SRShvan J. Raheem
Shvan J. Raheem
JLJason S. Lewis
Jason S. Lewis
EPEric W. Price
Eric W. Price

19 November 2020 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
ESElaheh Khozeimeh Sarbisheh
Elaheh Khozeimeh Sarbisheh
GRGuillaume Dewaele-Le Roi
Guillaume Dewaele-Le Roi
WSWhitney E. Shannon
Whitney E. Shannon
STSally Tan
Sally Tan
YXYujia Xu
Yujia Xu
EPEric W. Price
Eric W. Price

12 November 2020 in Inorganic Chemistry
Verified
Journal Article
Closed access
KSKelly L. Summers
Kelly L. Summers
ESElaheh Khozeimeh Sarbisheh
Elaheh Khozeimeh Sarbisheh
AZAmanda Zimmerling
Amanda Zimmerling
JCJulien J. H. Cotelesage
Julien J. H. Cotelesage
IPIngrid J. Pickering
Ingrid J. Pickering
EPEric W. Price
Eric W. Price

14 December 2022 in Inorganic Chemistry
Verified
Journal Article
Closed access
ASAkam K. Salih
Akam K. Salih
SRShvan J. Raheem
Shvan J. Raheem
MGMoralba Dominguez Garcia
Moralba Dominguez Garcia
WAWilliam K. Ahiahonu
William K. Ahiahonu
EPEric W. Price
Eric W. Price